Welcome to our dedicated page for Viaderma news (Ticker: VDRM), a resource for investors and traders seeking the latest updates and insights on Viaderma stock.
ViaDerma, Inc. reports developments in its specialty pharmaceutical business, including transdermal drug-delivery work, topical antibiotic products and wound-care commercialization. Company news has focused on its flagship tetracycline-based topical antibiotic, Vitastem, international distribution agreements, completed product shipments to Nigeria and market-development activity in the Middle East, Eastern Europe and India.
Recent updates also address operating results, financial-report posting, regulatory-compliance efforts and the company’s OTC market status. The company has described ongoing operations while evaluating strategic options related to its public-company status and disclosure practices.
ViaDerma, Inc. (OTC Pink: VDRM) has finalized a ten-year licensing agreement worth $12 million with a company in Dubai, granting exclusive rights to sell its products in the Middle East. The first payment of $600,000 is expected by August 5, 2021. Additionally, ViaDerma's partnership with a home health wound care network has expanded across nine states, generating $45,000 monthly in royalties. The company plans to hire an auditing firm within 30 to 60 days for financial audits necessary for an OTCQB listing application later this year.
ViaDerma, Inc. (OTC: VDRM) has expanded its licensing agreement with a home health wound care network, increasing monthly royalties from $35,000 to $40,000 due to the addition of two states. Expected revenue could reach $80,000 monthly by year-end. The company is also set to generate approximately $600,000 annually from a new limb salvage campaign. Additionally, President Dr. Chris Otiko will finalize a $12 million licensing agreement in Dubai by June 25, with an initial payment of $600,000 due upon conclusion.
ViaDerma, Inc. (OTC Pink: VDRM) is nearing a major order for its wound care product, Vitastem, from a significant healthcare network after successful testing. This order is projected to flow into hundreds of hospitals and nursing homes. Additionally, ViaDerma is expanding its licensing agreement to eight states, earning $5,000 per month for each state. The company plans to file its first quarter financials by May 17 and is addressing its temporary status with OTC Markets to return to Current Status.
ViaDerma, Inc. (OTC Pink: VDRM) reported substantial revenue growth for Q1 2021, expecting revenues to exceed $113,000, a remarkable increase of 5000% compared to $2,133 in Q1 2020. Online retail sales contributed over $23,000, up 978% year-over-year, while a licensing agreement brought in $90,000. The company eliminated all toxic convertible debt and is now debt-free, planning to self-fund future operations. ViaDerma seeks to list on OTCQB by securing audited financials and independent directors, while focusing on institutional clients for future sales.
ViaDerma, Inc. (VDRM) announced on March 16, 2021, that it has eliminated over $869,900 in toxic convertible debt, becoming completely debt-free. The company settled with creditors to convert outstanding notes into only 70 million shares, significantly reducing potential shareholder dilution. CEO Dr. Chris Otiko emphasized that this milestone allows the company to focus on increasing sales and self-funding future operations. Additionally, ViaDerma's licensing agreement for its Vitastem product has generated $30,000 in monthly revenue across six states, with planned expansions in the near future.